Division of Gastroenterology and Hepatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine, University of Pennsylvania, 836 Blockley Hall, 423 Guardian Drive, Philadelphia, PA, 19104-6021, USA.
Curr HIV/AIDS Rep. 2020 Aug;17(4):405-414. doi: 10.1007/s11904-020-00508-z.
Limited data exist on the prevalence, determinants, and outcomes of hepatitis delta virus (HDV) infection among HIV/hepatitis B virus (HBV)-coinfected persons. This review provides current evidence on the epidemiology, natural history, and treatment of HDV infection in patients with HIV/HBV coinfection and highlights future research needs.
Cross-sectional studies in Europe, Africa, South America, and Asia show that the prevalence of HDV among HIV/HBV-coinfected patients ranges from 1.2 to 25%. No studies have evaluated the prevalence of HDV infection among HIV/HBV-coinfected patients in the USA. HDV infection increases the risk of hepatic decompensation and hepatocellular carcinoma among HIV/HBV-coinfected patients. HDV treatment remains limited to pegylated interferon-alpha, which results in sustained virologic response in fewer than 25%. Data on the epidemiology, natural history, and treatment of HDV among HIV/HBV-coinfected persons remain limited. More research is needed to address these knowledge gaps in order to better manage HDV coinfection in HIV/HBV-coinfected patients.
关于 HIV/乙型肝炎病毒（HBV）共感染人群中乙型肝炎 delta 病毒（HDV）感染的流行率、决定因素和结局，相关数据有限。本综述提供了关于 HIV/HBV 共感染患者中 HDV 感染的流行病学、自然史和治疗的最新证据，并强调了未来的研究需求。
来自欧洲、非洲、南美洲和亚洲的横断面研究表明，HIV/HBV 共感染患者中 HDV 的流行率为 1.2%至 25%。尚无研究评估美国 HIV/HBV 共感染患者中 HDV 感染的流行率。HDV 感染增加了 HIV/HBV 共感染患者肝失代偿和肝细胞癌的风险。HDV 的治疗仍限于聚乙二醇干扰素-α，其在不到 25%的患者中产生持续病毒学应答。关于 HIV/HBV 共感染患者中 HDV 的流行病学、自然史和治疗的数据仍然有限。需要开展更多研究以解决这些知识空白，从而更好地管理 HIV/HBV 共感染患者的 HDV 共感染。
